Mrecist Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization Plus Durvalumab with or Without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma

B. Sangro,M. Kudo, J. P. Erinjeri,S. Qin,Z. Ren, S. Chan, Y. Arai,J. Heo, A. Mai, F. E. Penagos, Y. A. Lopez Chuken, J. H. Yoon,W. Y. Tak, T. Suttichaimongkol,M. Bouattour,S. M. Lin,M. Zotkiewicz, S. Ai, G. J. Cohen,R. Lencioni

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS（2024）

Cited 0|Views2

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined